Sarcopenic Obesity: When Low Muscle Mass and Excess Fat Occur Together

Sarcopenia refers to the progressive loss of skeletal muscle mass and strength that occurs with ageing. When sarcopenia occurs alongside excess body fat, the result is sarcopenic obesity — a condition that carries greater health risk than either sarcopenia or obesity alone. It is increasingly recognised as a distinct clinical entity with specific diagnostic criteria and management implications.

How common is sarcopenic obesity?

Prevalence estimates vary depending on the diagnostic criteria used, but sarcopenic obesity is thought to affect around 5–10% of the general adult population and up to 20–30% of adults over 65. It is more common in men than women and increases sharply with age. A 2022 systematic review in Ageing Research Reviews estimated that sarcopenic obesity affects approximately 11% of community-dwelling older adults worldwide.

Why is the combination particularly harmful?

Sarcopenia and obesity interact in ways that amplify their individual effects. Excess adipose tissue — particularly visceral fat — releases pro-inflammatory cytokines that accelerate muscle protein breakdown. Conversely, low muscle mass reduces the body's capacity to oxidise fat, promoting further fat accumulation. This creates a self-reinforcing cycle.

The health consequences are substantial. Compared to people with obesity alone or sarcopenia alone, those with sarcopenic obesity have:

• Higher rates of cardiovascular disease and metabolic syndrome
• Greater risk of physical disability and falls
• Poorer surgical outcomes and longer hospital stays
• Higher all-cause mortality — a 2020 meta-analysis in Obesity Reviews found a 24% higher mortality risk compared to non-sarcopenic, non-obese individuals

Why is it easily missed?

Standard BMI-based assessment does not detect sarcopenic obesity. A person may have a BMI in the overweight or obese range while having critically low muscle mass — a pattern sometimes called "normal-weight obesity" or "overfat". Conversely, muscle loss may be masked by stable body weight as fat replaces muscle tissue. Accurate diagnosis requires body composition assessment — such as DEXA scanning, bioelectrical impedance analysis, or CT imaging — alongside measures of muscle strength and physical function.

How is sarcopenic obesity managed?

Management requires a dual focus: reducing fat mass while preserving or building muscle. This means combining a modest calorie deficit with adequate protein intake (at least 1.2–1.6g per kilogram of body weight per day) and progressive resistance training. Rapid weight loss without resistance exercise risks accelerating muscle loss and worsening the underlying condition.

A doctor-led programme can assess your body composition and design a plan that addresses both components. Contact Weight Loss Wales to book your consultation.